Disproportional inflation of clinical trial costs: why we should care, and what we should do about it
Supplementary Figure 1 | ClinicalTrials.gov records, segmented by trial phase (I, II, III) from 1 January 1980 to 31 December 2022. Data presented are means (line) and 95% confidence intervals (shade). The y axis refers to record characteristics as mentioned on the ClinicalTrials.gov website. Note: ClinicalTrials.gov did not provide a comprehensive representation of trials for new drugs until after the ICMJE mandate in 2005 (refer to doi: 10.7326/0003-4819-141-6-200409210-00109 for details). Data before that time therefore may be less complete and should be interpreted taking this into account. a, Average number of outcome measures (that is, endpoints). b, Average enrollment (that is, enrolled subjects). Data from was exported directly from ClinicalTrials.gov on 1 March 2023 using the following filters: ‘recruiting’, ‘not yet recruiting’, ‘active not recruiting’, ‘completed’, ‘enrolling by invitation’, ‘suspended’, ‘terminated’, ‘unknown status’, ‘interventional’, ‘Early Phase 1’, ‘Phase 1’, ‘Phase 2’ and ‘Phase 3’.